Navin Saran, MD
Addiction Medicine · Anaheim, CANPI 1396814570
Payments from drug & device makers
Across 5 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$24
- Sun Pharmaceutical Industries Inc.$23
- Lilly USA, LLC$23
- Otsuka America Pharmaceutical, Inc.$21
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$14
What the payments were for
- Food & beverage$105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
How this compares
$105 in reported general payments places this provider in the 30th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $97,765 |
| JanuviaSitagliptin Phosphate | 108 | $69,027 |
| MyrbetriqMirabegron | 78 | $34,222 |
| XareltoRivaroxaban | 40 | $25,824 |
| JardianceEmpagliflozin | 38 | $24,678 |
| EmsamSelegiline | 11 | $24,268 |
| TradjentaLinagliptin | 60 | $19,103 |
| Metformin Er GastricMetformin Hcl | 22 | $16,351 |
| EntrestoSacubitril/Valsartan | 26 | $14,031 |
| Atorvastatin Calcium | 1,240 | $13,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,321 |
| Levothyroxine Sodium | 910 | $10,169 |
| Lurasidone Hcl | 38 | $8,244 |
| Repatha SureclickEvolocumab | 14 | $7,724 |
| VascepaIcosapent Ethyl | 36 | $7,496 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Anaheim
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Faried BanimahdSanta Ana$16K
- Abraham MalkinLos Angeles$12K
- Jonathan ReitmanBeverly Hills$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.